---
title: "CMBI Cuts AKESO  TP to HKD99.34; HARMONi-3 Remains Key Catalyst"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305919330.md"
description: "CMBI lowered AKESO's target price to HKD99.34 from HKD138.42 after the FDA declined approval for ivonescimab in second-line EGFR-mutated NSCLC due to insufficient overall survival data. Despite maintaining a 'Buy' rating, CMBI emphasized that the HARMONi-3 trial remains the key catalyst for the drug's future success and investment thesis."
datetime: "2026-11-18T05:48:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305919330.md)
  - [en](https://longbridge.com/en/news/305919330.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305919330.md)
generator: "portal-rs"
---

# CMBI Cuts AKESO  TP to HKD99.34; HARMONi-3 Remains Key Catalyst

CMBI issued a research report stating that the US Food and Drug Administration (FDA) declined to approve ivonescimab combined with chemotherapy for second-line EGFR-mutated non-small cell lung cancer (NSCLC), believing that while progression-free survival (PFS) improved, overall survival (OS) did not reach statistical significance and therefore failed to establish a positive benefit-risk profile. The broker maintained its "Buy" rating on AKESO (09926.HK) -2.900 (-4.685%) Short selling $204.82M; Ratio 24.236% and, based on DCF valuation, lowered its TP by 28.2% from HKD138.42 to HKD99.34.

The broker noted that although the global HARMONi trial achieved significant PFS improvement, the primary OS analysis did not reach significance (hazard ratio of 0.79, p=0.057). Subsequent longer follow-up showed OS hazard ratios of 0.76 for the overall, Asian and Western populations, but these were post-hoc analyses and insufficient to change the FDA's assessment. Second-line EGFR-mutated NSCLC is a relatively small indication, accounting for less than 5% of the broker's estimate of ivonescimab's global peak sales, while the limitations of HARMONi cannot be directly extrapolated to the broader Summit development program.

The broker believes HARMONi-3 is more critical in determining whether ivonescimab can outperform existing standard therapies in large indications. The trial was specifically designed as a multi-regional first-line study, with statistical power established separately for squamous and non-squamous cohorts. The required number of PFS events for the primary analysis of the squamous cohort is expected to be reached in 4Q26, alongside a planned early interim OS analysis. The PFS event threshold for the non-squamous cohort is expected to be reached in 1H27.

The broker said the Complete Response Letter (CRL) will delay US commercialization, while HARMONi-3 and successful combination therapy trials remain central to the investment thesis for AKESO. (da/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-18 12:25.)

### Related Stocks

- [09926.HK](https://longbridge.com/en/quote/09926.HK.md)

## Related News & Research

- [Akeso Says FDA Complete Response Letter May Explain Unusual Share Price Moves](https://longbridge.com/en/news/305612661.md)
- [Nomura Downgrades AKESO  to Neutral, Cuts TP to HKD94](https://longbridge.com/en/news/305613245.md)
- [Akeso's Gumokimab Wins China Approval for Active Ankylosing Spondylitis](https://longbridge.com/en/news/305622467.md)
- [China Accepts Akeso’s Ivonescimab Application for Biliary Tract Cancer](https://longbridge.com/en/news/305757945.md)
- [UBS: AKESO  Partner Receives FDA Complete Response Letter for ivonescimab Plus Chemotherapy BLA, Slightly Negative](https://longbridge.com/en/news/305605601.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**